CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 692 enrolled
Drug / intervention
Crizotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679170
NCT02679170N/ACompleted
CompareCT.gov

Observational Study to IDEntify Patients With Advanced/Metastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Pfizer·observational·Posted Feb 10, 2016·Updated Aug 9, 2024

In Brief

An observational study evaluating Crizotinib for Non-Small Cell Lung Cancer. Completed, enrolled 692 participants across 32 sites.

Detailed Summary

Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK\&ROS)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 10, 2016
Enrollment StartJun 29, 2016
Primary CompletionMay 4, 2022
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.4 years ago

Interventions

Crizotinibdrug

Treatment with crizotinib following routine clinical practice